Endoglin/CD105, a homodimeric, transmembrane glycoprotein composed of disulphide-linked subunits of 95 kDa. It is the most reliable marker of proliferation of endothelial cells. It is over expressed on tumor neovasculature. The available information indicates Endoglin as a powerful diagnostic and therapeutic target in human malignancies, through the imaging and the inhibition of tumor related angiogenesis.

PRODUCT

1. Each vial contains the indicated amount of IgG (caprylic acid purified) in 0.1% gelatine and 0.05% NaN3.

2. Unpurified reagent is provided at the indicated amounts with 0.1% NaN3.

Centrifuge the vial prior to use.

SPECIFICITY

Mab MAEND3 (IgG1) recognizes native CD105.

STORAGE

Store frozen and avoid repeated freeze-thawing. Stable for 2 yrs.

SHIPPING CONDITIONS

Room temperature.

RESEARCH USE

This antibody is for laboratory research use only, not for human or in-vivo use.

APPLICATIONS

Flow cytometry, 10-20 µg/ml on human umbilical vein endothelial cells (HUVEC) (ref. 1,2,3).

Immunohistochemistry (fluorescence , enzymatic), Acetone-fixed cryostat sections (10-20 µg/ml).

Immunoprecipitation, 5 µg, using rabbit anti-mouse Ig and protein ASepharose beads (ref.1).

Dot Blot Assay for soluble Endoglin, Mab MAEND3 (5 µg/ml) recognizes soluble Endoglin in conditioned medium from HUVEC, various cancer cell lines, and in sera of patients with melanoma and myeloid malignancies (ref. 3,4).

REFERENCES
1. J Cancer (1996) 74: 1586-1591.
2. Clin Cancer Res (2000) 6: 2037-2043.
3. J Cell Physiol (2001) 188: 1-7.
4. J Cell Physiol (2002) 194: 17.